Drugs / myoblast
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00626314 | Mar 2008 → Mar 2010 | cardiomyopathy | Mytogen, Inc. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | myoblast | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00626314 ↗ |
| Modality | Cell therapy | “autologous skeletal myoblast transplantation” NCT00626314 ↗ |
| Route | Other | “delivered by endomyocardial injection” NCT00626314 ↗ |